|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver transplantation for hepatocellular carcinoma:Role of inflammatory and immunological state on recurrence and prognosis显示文摘Criteria for liver transplantation(LT)for hepatocellular carcinoma(HCC)and post-LT indicators of prognosis are historically based on the measurement of the tumor mass.Recently,high throughput technologies have increased the prediction of recurrence,but these tools are not yet routinely available.The interaction between HCC and the immune system has revealed an imbalance of lymphocyte phenotypes in the peritumoral tissue,and the increase of regulatory T cells with respect to cytotoxic lymphocytes has been linked to a higher rate of post-LT HCC recurrence.Moreover,some inflammatory markers have shown good reliability in predicting cancer reappearance after surgery,as a result of either a systemic inflammatory response or a decreased capacity of the organism to control the tumor growth.Among these markers,the neutrophil-tolymphocyte ratio appears to be the most promising and easily available serum parameter able to predict HCC recurrence after LT and following other types of treatment,although the exact mechanisms determining its elevation have not been clarified.Post-LT immunosuppression may impact on cancer control,and the exposure to high levels of calcineurin inhibitors or other immunusuppressants has recently emerged as a negative prognostic factor for HCC recurrence and patient survival.Despite the absence of prospective randomized trials,inhibitors of the mammalian target of rapamycin have been shown to be associated with lower rates of tumor recurrence compared to other immunosuppressors,suggesting their use especially in patients with HCC exceeding the conventional indication criteria for LT. | Matteo Cescon Valentina Rosa Bertuzzo Giorgio Ercolani Matteo Ravaioli Federica Odaldi Antonio Daniele Pinna | 2013 | World Journal of Gastroenterology2013，19，48： | 8 |
| 2 | Non-invasive tests for the prediction of primary hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC)is one of the most common malignancies in the world and it is one of the main complications of cirrhosis and portal hypertension.Even in the presence of a well-established follow-up protocol for cirrhotic patients,to date poor data are available on predictive markers for primary HCC occurrence in the setting of compensated advanced chronic liver disease patients(cACLD).The gold standard method to evaluate the prognosis of patients with cACLD,beyond liver fibrosis assessed with histology,is the measurement of the hepatic venous pressure gradient(HVPG).An HVPG≥10 mmHg has been related to an increased risk of HCC in cACLD patients.However,these methods are burdened by additional costs and risks for patients and are mostly available only in referral centers.In the last decade increasing research has focused on the evaluation of several,simple,non-invasive tests(NITs)as predictors of HCC development.We reviewed the currently available literature on biochemical and ultrasound-based scores developed for the noninvasive evaluation of liver fibrosis and portal hypertension in predicting primary HCC.We found that the most reliable methods to assess HCC risk were the liver stiffness measurement,the aspartate aminotransferase to platelet ratio index score and the fibrosis-4 index.Other promising NITs need further investigations and validation for different liver disease aetiologies. | Giovanni Marasco Antonio Colecchia Giovanni Silva Benedetta Rossini Leonardo Henry Eusebi Federico Ravaioli Elton Dajti Luigina Vanessa Alemanni Luigi Colecchia Matteo Renzulli Rita Golfieri Davide Festi | 2020 | World Journal of Gastroenterology2020，26，24： | 8 |
| 3 | Liver transplantation for hepatic tumors:a systematic review显示文摘Improvements in the medical and pharmacological management of liver transplantation(LT)recipients have led to a better long-term outcome and extension of the indications for this procedure.Liver tumors are relevant to LT;however,the use of LT to treat malignancies remains a debated issue because the high risk of recurrence.In this review we considered LT for hepatocellular carcinoma(HCC),cholangiocarcinoma(CCA),liver metastases(LM)and other rare tumors.We reviewed the literature,focusing on the past 10 years.The highly selected Milan criteria of LT for HCC(single nodule<5 cm or up to 3 nodules<3cm)have been recently extended by a group from the University of S.Francisco(1 lesion<6.5 cm or up to3 lesions<4.5 cm)with satisfying results in terms of recurrence-free survival and the'up-to-seven criteria'.Moreover,using these criteria,other transplant groups have recently developed downstaging protocols,including surgical or loco-regional treatments of HCC,which have increased the post-operative survival of recipients.CCA may be treated by LT in patients who cannot undergo liver resection because of underlying liver disease or for anatomical technical challenges.A well-defined protocol of chemoirradiation and staging laparotomy before LT has been developed by the Mayo Clinic,which has resulted in long term diseasefree survival comparable to other indications.LT for LM has also been investigated by multicenter studies.It offers a real benefit for metastases from neuroendocrine tumors that are well differentiated and when a major extrahepatic resection is not required.If LT is an option in these selected cases,liver metastases from colorectal cancer is still a borderline indication because data concerning the disease-free survival are still lacking.Hepatoblastoma and hemangioendothelioma represent rare primary tumors for which LT is often the only possible and effective cure because of the frequent multifocal,intrahepatic nature of the disease.LT is a very promising procedure for both primary and secondary liver malignancies;however,it needs an accurate evaluation of the costs and benefits for each indication to balance the chances of cure with actual organ availability. | Matteo Ravaioli Giorgio Ercolani Flavia Neri Matteo Cescon Giacomo Stacchini Massimo Del Gaudio Alessandro Cucchetti Antonio Daniele Pinna | 2014 | World Journal of Gastroenterology2014，20，18： | 8 |
| 4 | Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: Is it necessary?显示文摘AIM: To assess the safety and effectiveness of prophylaxis for venous thromboembolism (VTE) in a large population of patients with hepatocellular carcinoma (HCC) on cirrhosis.METHODS: Two hundred and twenty nine consecutive cirrhotic patients with HCC who underwent hepatic resection were retrospectively evaluated to assess whether there was any difference in the incidence of thrombotic or hemorrhagic complications between those who received and those who did not receive prophylaxis with low-molecular weight heparin.Differences and possible effects of the following parameters were investigated: age,sex,Child-Pugh and model for end-stage liver disease (MELD) score,platelet count,presence of esophageal varices,type of hepatic resection,duration of surgery,intraoperative transfusion of blood and fresh frozen plasma (FFP),body mass index,diabetes and previous cardiovascular disease.RESULTS: One hundred and fifty seven of 229 (68.5%) patients received antithromboembolic prophylaxis (group A) while the remaining 72 (31.5%) patients did not (group B).Patients in group B had higher Child-Pugh and MELD scores,lower platelet counts,a higher prevalence of esophageal varices and higher requirements for intraoperative transfusion of FFP.The incidence of VTE and postoperative hemorrhage was 0.63% and 3.18% in group A and 1.38% and 1.38% in group B,respectively;these differences were not significant.None of the variables analyzed including prophylaxis proved to be risk factors for VTE,and only the presence of esophageal varices was associated with an increased risk of bleeding.CONCLUSION: Prophylaxis is safe in cirrhotic patients without esophageal varices;the real need for prophylaxis should be better assessed. | Marco Vivarelli Matteo Zanello Chiara Zanfi Alessandro Cucchetti Matteo Ravaioli Massimo Del Gaudio Matteo Cescon Augusto Lauro Eva Montanari Gian Luca Grazi Antonio Daniele Pinna | 2010 | World Journal of Gastroenterology2010，16，17： | 6 |
| 5 | Is Portal Hypertension a Contraindication to Hepatic Resection?显示文摘 | Alessandro Cucchetti Giorgio Ercolani Marco Vivarelli Matteo Cescon Matteo Ravaioli Giovanni Ramacciato Gian Luca Grazi Antonio Daniele Pinna | 2009 | Annals of Surgery2009，，6： | 5 |
| 6 | Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence显示文摘 | Giorgio Ercolani Gian Luca Grazi Matteo Ravaioli Massimo Del Gaudio Andrea Gardini Matteo Cescon Giovanni Varotti Francesco Cetta Antonino Cavallari | 2003 | Annals of Surgery2003，，4： | 2 |
| 7 | Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors: Reassessment of Risk Factors for Tumor Recurrence显示文摘 | Marco Vivarelli Alessandro Cucchetti Giuliano La Barba Matteo Ravaioli Massimo Del Gaudio Augusto Lauro Gian Luca Grazi Antonio Daniele Pinna | 2008 | Annals of Surgery2008，，5： | 2 |
| 8 | Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation显示文摘 | Fabio Piscaglia Alice Gianstefani Matteo Ravaioli Rita Golfieri Alberta Cappelli Emanuela Giampalma Elisabetta Sagrini Grazia Imbriaco Antonio Daniele Pinna Luigi Bolondi | 2010 | Liver Transpl2010，，： | 2 |
| 9 | Hepatocellular Carcinomas and Primary Liver Tumors as Predictive Factors for Postoperative Mortality after Liver Resection: A Meta-Analysis of More than 35,000 Hepatic Resections显示文摘 | Ramacciato Giovanni D’Angelo Francesco Baldini Rossella Petrucciani Niccoló Antolino Laura Aurello Paolo Nigri Giuseppe Bellagamba Riccardo Pezzoli Francesca Balesh Albert Cucchetti Alessandro Cescon Matteo Del Gaudio Massimo Ravaioli Matteo | 2012 | EN2012，，4： | 2 |
| 10 | Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population显示文摘 | Alessandro Cucchetti MD Fabio Piscaglia MD Eugenio Caturelli MD Luisa Benvegnù MD Marco Vivarelli MD Giorgio Ercolani MD Matteo Cescon MD Matteo Ravaioli MD Gian Luca Grazi MD Luigi Bolondi MD Antonio Daniele Pinna MD | 2009 | Annals of Surgical Oncology2009，，2： | 2 |
| 11 | Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate显示文摘 | Matteo Cescon Alessandro Cucchetti Matteo Ravaioli Antonio Daniele Pinna | 2012 | Journal of Hepatology2012，，： | 1 |
| 12 | Hospital Volume, Margin Status, and Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma显示文摘 | La Torre Marco Nigri Giuseppe Ferrari Linda Cosenza Giulia Ravaioli Matteo Ramacciato Giovanni | 2012 | EN2012，，2： | 1 |
| 13 | Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center显示文摘 | Giorgio Ercolani Matteo Zanello Gian Luca Grazi Matteo Cescon Matteo Ravaioli Massimo Gaudio Gaetano Vetrone Alessandro Cucchetti Giovanni Brandi Giovanni Ramacciato Antonio Daniele Pinna | 2010 | Journal of Hepato-Biliary-Pancreatic Sciences2010，，3： | 1 |
| 14 | Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?显示文摘Dear Editor:In the last two decades,the indications of liver transplantation(LT)for primary and secondary hepatobiliary malignancies have been increasingly expanded.Although this attractive option still represents the“last court of appeal”in cancer patients,the role of LT is well established in hepatocellular carcinoma(HCC),where transplantation has also demonstrated a benefit for selected patients affected by peri-hilar cholangiocarcinoma,intrahepatic cholangiocarcinoma,and neuroendocrine tumors[1].Recently,the interest in LT in liver-limited stage IV colorectal cancer(CRC)has increased due to recent advances in transplantation techniques that have led to a re-evaluation of this approach. | Giovanni Brandi Angela Dalia Ricci Alessandro Rizzo Chiara Zanfi Simona Tavolari Andrea Palloni Stefania De Lorenzo Matteo Ravaioli Matteo Cescon | 2020 | Cancer Communications2020，40，9： | 1 |
| 15 | Impact of biliary complications in right lobe living donor liver transplantation显示文摘 | Giovanni Ramacciato Giovanni Varotti Cristiano Quintini Michele Masetti Fabrizio Benedetto Gian Luca Grazi Giorgio Ercolani Matteo Cescon Matteo Ravaioli Augusto Lauro Antonio Pinna | 2006 | Transplant International2006，，2： | 1 |
| 16 | Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular Carcinoma显示文摘 | Marco Vivarelli Alessandro Dazzi Matteo Zanello Alessandro Cucchetti Matteo Cescon Matteo Ravaioli Massimo Del Gaudio Augusto Lauro Gian Luca Grazi Antonio Daniele Pinna | 2010 | Transplantation2010，，2： | 1 |
| 17 | Portal Vein Thrombosis and Liver Transplantation: Evolution During 10 Years of Experience at the University of Bologna显示文摘 | Matteo Ravaioli Matteo Zanello Gian Luca Grazi Giorgio Ercolani Matteo Cescon Massimo Del Gaudio Alessandro Cucchetti Antonio Daniele Pinna | 2011 | Annals of Surgery2011，，2： | 1 |
| 18 | Is Portal Hypertension a Contraindication to Hepatic Resection?显示文摘 | Alessandro Cucchetti Giorgio Ercolani Marco Vivarelli Matteo Cescon Matteo Ravaioli Giovanni Ramacciato Gian Luca Grazi Antonio Daniele Pinna | 2009 | Annals of Surgery2009，，6： | 1 |
| 19 | Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population显示文摘 | Alessandro Cucchetti MD Fabio Piscaglia MD Eugenio Caturelli MD Luisa Benvegnù MD Marco Vivarelli MD Giorgio Ercolani MD Matteo Cescon MD Matteo Ravaioli MD Gian Luca Grazi MD Luigi Bolondi MD Antonio Daniele Pinna MD | 2009 | Annals of Surgical Oncology2009，，2： | 1 |
| 20 | The Role of Lymphadenectomy for Liver Tumors: Further Considerations on the Appropriateness of Treatment Strategy显示文摘 | Giorgio Ercolani Gian Luca Grazi Matteo Ravaioli Walter Franco Grigioni Matteo Cescon Andrea Gardini Massimo Del Gaudio Antonino Cavallari | 2004 | Annals of Surgery2004，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员